ImmunityBio stock rises after 85% response rate in bladder cancer study, topping BCG alone; FDA filing planned for 2026.

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across ...

On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global ...

Why ImmunityBio’s latest bladder cancer trial update matters for the stock ImmunityBio (IBRX) has attracted fresh attention after reporting that its Phase 2 QUILT 2.005 trial in BCG naïve non muscle ...

On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal ...

ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ...

We recently published 10 Stocks Winning the Market. ImmunityBio Inc. (NASDAQ:IBRX) was one of the best performers on Tuesday.

The clinical stage immunotherapy company logged a five-fold increase in fourth-quarter revenue of $38.3 million, and beat Wall Street's forecast of $37.9 million, according to FactSet. The top-line ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

ImmunityBio (IBRX) stock gains as EU grants conditional approval for the company's bladder cancer drug, Anktiva. Read more ...